Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Marion Feuilly"'
Autor:
Matthieu Carton, Johanna Peña Del Castillo, Jean-Baptiste Colin, Milena Kurtinecz, Marion Feuilly, Gaëlle Pierron, Pierre Arvis, Soumeya Khadidja Khadir, Monika Sparber-Sauer, Daniel Orbach
Publikováno v:
Future Oncology.
The EPI VITRAKVI study is a retrospective study designed to place the results of the single-arm Phase I/II larotrectinib SCOUT trial into context by comparison with external historical controls. Its primary objective is to compare the time to medical
Autor:
Jennifer Evans, Jackie Herman, Mohid S. Khan, Dirk Van Genechten, Marion Feuilly, Sebastian J C M M Neggers, David Cella
Publikováno v:
Advances in Therapy
Advances in Therapy, 38(2), 969-993. Springer International Publishing AG
Advances in Therapy, 38(2), 969-993. Springer International Publishing AG
Introduction Somatostatin analogs (SSAs) are used to treat neuroendocrine tumors (NETs) and acromegaly. Two first-generation SSAs, octreotide long-acting release (OCT LAR) and lanreotide autogel/depot (LAN), are available. A systematic literature rev
Autor:
Toni K. Choueiri, Michael J. Morris, Jie Meng, Aaron D. Falchook, Darren R. Feldman, Johanna Lister, Ronald C. Chen, Marion Feuilly, Daniel J. George, Florence Marteau
Publikováno v:
Cancer
Background Cabozantinib Versus Sunitinib as Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial (CABOSUN) was a randomized, open‐label, phase 2 trial evaluating
Autor:
Kimberly Webster, Sara Shaunfield, Karen Kaiser, Marion Feuilly, David Cella, Daniel M. Halperin, James C. Yao, Leilani Lacson, Al B. Benson, George J. Greene, Florence Marteau, Susan Yount, Simron Singh
Publikováno v:
Neuroendocrinology. 111:850-862
Objective: To develop a symptom-focused index to evaluate representative symptoms, treatment side effects, and emotional and functional well-being of patients with carcinoid syndrome (CS). Methods: The development of the Functional Assessment of Canc
Autor:
Enrique Grande, Lucie Keeber, Amy Buchanan-Hughes, Thomas Walter, Marion Feuilly, Mohid S. Khan, Emma Worthington
Publikováno v:
World Journal of Gastroenterology
BACKGROUND Approximately 20% of patients with neuroendocrine tumours (NETs) develop carcinoid syndrome (CS), characterised by flushing and diarrhoea. Somatostatin analogues or telotristat can be used to control symptoms of CS through inhibition of se
Publikováno v:
Advances in Therapy
Introduction Somatostatin analogues are used to treat symptoms and slow tumour progression in patients with neuroendocrine tumours (NETs) and carcinoid syndrome and to reduce hormone secretion and pituitary tumour volume in patients with acromegaly.
Autor:
Peter Myrenfors, D. Mark Pritchard, Marion Feuilly, Kelly Fust, Michele Kohli, Simron Singh, Florence Marteau, Michael Maschio
Publikováno v:
PHARMACOECONOMICS
Carcinoid syndrome, a rare condition in patients with neuroendocrine tumours, characterised by flushing and diarrhoea, severely affects patients’ quality of life. The current carcinoid syndrome standard of care includes somatostatin analogues, but
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e400deab76d7fb779a3a41ac069c0b8
Publikováno v:
Journal of the Endocrine Society
Background: A new lanreotide autogel/depot (LAN) syringe was developed based on feedback from a human factors study to improve user experience. Methods: PRESTO was a multinational, simulated-use study in nurses with ≥2 years’ experience injecting
Autor:
Lucie Keeber, Mohid S. Khan, Marion Feuilly, Enrique Grande, Amy Buchanan-Hughes, Thomas Walter
Publikováno v:
Endocrine Abstracts.
Autor:
Anna Liovas, Winson Y. Cheung, Callahan Laforty, Marion Feuilly, Jonathan M. Loree, Heather McKechnie
Publikováno v:
Journal of Clinical Oncology. 38:608-608
608 Background: Somatostatin analogue (SSA) use is indicated in acromegaly and neuroendocrine tumours for symptomatic relief and tumour control. Two long-acting SSAs (lanreotide and octreotide) are currently available, but comparative real-world data